Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

PHASE3CompletedINTERVENTIONAL
Enrollment

291

Participants

Timeline

Start Date

May 2, 2017

Primary Completion Date

June 25, 2018

Study Completion Date

June 25, 2018

Conditions
Scabies
Interventions
DRUG

spinosad topical suspension, 0.9%

Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.

OTHER

Placebo

Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.

Trial Locations (5)

33015

San Marcus Research, Miami

33144

L&C Professional Medical Research Institute, Miami

33407

LSRN Research, West Palm Beach

34744

The Chappel Group Research, Kissimmee

95758

Elk Grove Clinical Research, Elk Grove

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Concentrics Research

OTHER

lead

ParaPRO LLC

INDUSTRY